BeiGene Ltd.

China Merchants CSI Vaccine and Biotechnology ETF (561920) closed down 0.43% on Dec 9, with a turnover of 173,800 yuan. The fund, established on Mar 15, 2023, has seen a 14.01% decrease in shares and a 32.33% decrease in scale since the beginning of the year. Fund manager Hou Hao has managed the ETF since Jul 13, 2024, achieving a 16.56% return. The ETF's top holdings include Zhifei Biotech, Wantai Biotech, and others.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

Loncastuximab tesirine (Zynlonta) combined with rituximab showed a 97% response rate at 12 weeks in a phase II trial for relapsed or refractory follicular lymphoma, with 67% achieving complete response. The combination demonstrated high progression-free and overall survival rates, suggesting it as a promising treatment option for second-line and later follicular lymphoma.

DelveInsight's report on Urothelial Carcinoma Market (2020-2034) highlights market trends, epidemiology, and key companies/therapies. The market size was ~USD 900 million in 2023, expected to grow significantly. Key companies include Merck, Bristol Myers Squibb, and others. Therapies like KEYTRUDA and OPDIVO are prominent. The U.S. leads in market share and incident cases. Pipeline candidates and increased awareness drive market growth.

Jazz Pharmaceuticals to host a webcast on Dec 11, 2024, to discuss Ziihera® (zanidatamab-hrii), a chemotherapy-free dual HER2-targeted bispecific antibody for biliary tract cancer (BTC), approved by the FDA on Nov 20, 2024.

Jazz Pharmaceuticals to host a webcast on December 11, 2024, to discuss clinical data, patient need, and commercialization strategy for Ziihera® (zanidatamab-hrii), a chemotherapy-free dual HER2-targeted bispecific antibody for biliary tract cancer (BTC), recently approved by the FDA.

Pharmaceutical and biotech companies often change names to reflect mission and focus. Notable changes include J&J renaming Janssen to Johnson & Johnson Innovative Medicine, BeiGene becoming BeOne Medicines, Vaccitech rebranding as Barinthus Biotherapeutics, Cullinan Oncology shifting to Cullinan Therapeutics, and Eliem Therapeutics renaming to Climb Bio.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

FDA decisions in December include BeiGene's Tevimbra for gastric cancer, Ionis Pharma's Olezarsen for familial chylomicronemia syndrome, Lexicon Pharma's Zynquista for type 1 diabetes, AstraZeneca's Datopotamab deruxtecan for lung cancer, Zealand Pharma's Glepaglutide for short bowel syndrome, Rhythm Pharma's IMCIVREE for obesity in children, Soleno's DCCR for Prader-Willi syndrome, Checkpoint's Cosibelimab for skin cancer, Mirum's Chenodiol for cerebrotendinous xanthomatosis, Bristol-Myers' subcutaneous Opdivo, and Neurocrine's Crinecerfont for congenital adrenal hyperplasia.

BeiGene, Ltd. (NASDAQ: BGNE, HKEX: 06160, SSE: 688235) plans to change its name to BeOne Medicines Ltd. and will host an investor webcast on December 16, 2024, featuring updates on its oncology portfolio and pipeline, including key presentations at ASH and the San Antonio Breast Cancer Symposium.